Correlation Between Exelixis and Mereo BioPharma

Can any of the company-specific risk be diversified away by investing in both Exelixis and Mereo BioPharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Exelixis and Mereo BioPharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Exelixis and Mereo BioPharma Group, you can compare the effects of market volatilities on Exelixis and Mereo BioPharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Exelixis with a short position of Mereo BioPharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Exelixis and Mereo BioPharma.

Diversification Opportunities for Exelixis and Mereo BioPharma

-0.71

Correlation Coefficient

Exelixis  Mereo BioPharma

Pay attention - limited upside

The 3 months correlation between Exelixis and Mereo is -0.71. Overlapping area represents the amount of risk that can be diversified away by holding Exelixis and Mereo BioPharma Group in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Mereo BioPharma Group and Exelixis is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Exelixis are associated (or correlated) with Mereo BioPharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Mereo BioPharma Group has no effect on the direction of Exelixis i.e., Exelixis and Mereo BioPharma go up and down completely randomly.

Pair Corralation between Exelixis and Mereo BioPharma

Given the investment horizon of 90 days Exelixis is expected to under-perform the Mereo BioPharma. But the stock apears to be less risky and, when comparing its historical volatility, Exelixis is 3.14 times less risky than Mereo BioPharma. The stock trades about -0.19 of its potential returns per unit of risk. The Mereo BioPharma Group is currently generating about 0.1 of returns per unit of risk over similar time horizon. If you would invest  347.00  in Mereo BioPharma Group on October 6, 2024 and sell it today you would earn a total of  26.00  from holding Mereo BioPharma Group or generate 7.49% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Exelixis  vs.  Mereo BioPharma Group

Exelixis

Risk-Adjusted Performance

14 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Exelixis are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. Despite quite weak technical and fundamental indicators, Exelixis disclosed solid returns over the last few months and may actually be approaching a breakup point.

Mereo BioPharma Group

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Mereo BioPharma Group has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unfluctuating performance, the Stock's technical and fundamental indicators remain healthy and the recent disarray on Wall Street may also be a sign of long period gains for the firm investors.

Pair Trading with Exelixis and Mereo BioPharma

The main advantage of trading using opposite Exelixis and Mereo BioPharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Exelixis position performs unexpectedly, Mereo BioPharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mereo BioPharma will offset losses from the drop in Mereo BioPharma's long position.

The idea behind Exelixis and Mereo BioPharma Group pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.